Cardiol Therapeutics Inc
CRDL1.010USD
0.000
收盘 12/19, 16:00（美东）报价延迟15分钟
88.33M总市值
亏损市盈率 TTM
关于 Cardiol Therapeutics Inc 公司
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Cardiol Therapeutics Inc简介
公司代码CRDL
公司名称Cardiol Therapeutics Inc
上市日期Dec 20, 2018
CEOElsley (David)
员工数量18
证券类型Ordinary Share
年结日Dec 20
公司地址602-2265 Upper Middle Road East
城市OAKVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编L6H 0G5
电话12899100850
网址https://www.cardiolrx.com/
公司代码CRDL
上市日期Dec 20, 2018
CEOElsley (David)
Cardiol Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Peter Pekos
Mr. Peter Pekos
Independent Director
Independent Director
506.04K
+8.29%
Mr. Colin George Stott
Mr. Colin George Stott
Independent Director
Independent Director
142.50K
--
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
133.33K
+11.11%
Ms. Jennifer M. Chao
Ms. Jennifer M. Chao
Independent Director
Independent Director
133.33K
+11.11%
Mr. Bernard Lim
Mr. Bernard Lim
Chief Operating Officer
Chief Operating Officer
40.00K
+33.33%
Dr. Andrew Hamer
Dr. Andrew Hamer
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
--
--
Mr. Trevor Burns
Mr. Trevor Burns
Investor Relations
Investor Relations
--
--
Dr. Guillermo Torre-Amione, M.D., Ph.D.
Dr. Guillermo Torre-Amione, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Michael J. Willner, Esq.
Mr. Michael J. Willner, Esq.
Independent Director
Independent Director
--
--
Mr. David Elsley
Mr. David Elsley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Peter Pekos
Mr. Peter Pekos
Independent Director
Independent Director
506.04K
+8.29%
Mr. Colin George Stott
Mr. Colin George Stott
Independent Director
Independent Director
142.50K
--
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
133.33K
+11.11%
Ms. Jennifer M. Chao
Ms. Jennifer M. Chao
Independent Director
Independent Director
133.33K
+11.11%
Mr. Bernard Lim
Mr. Bernard Lim
Chief Operating Officer
Chief Operating Officer
40.00K
+33.33%
Dr. Andrew Hamer
Dr. Andrew Hamer
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Tejara Capital Ltd.
5.16%
Elsley (David G)
1.35%
Willner (Michael Jay)
0.87%
Hamer (Andrew Warwick M.D.)
0.67%
Global X Investments Canada Inc.
0.67%
其他
91.27%
持股股东
持股股东
占比
Tejara Capital Ltd.
5.16%
Elsley (David G)
1.35%
Willner (Michael Jay)
0.87%
Hamer (Andrew Warwick M.D.)
0.67%
Global X Investments Canada Inc.
0.67%
其他
91.27%
股东类型
持股股东
占比
Investment Advisor
7.60%
Individual Investor
4.30%
Research Firm
1.31%
Investment Advisor/Hedge Fund
1.29%
Hedge Fund
1.17%
其他
84.33%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
92
11.26M
7.89%
+2.50M
2025Q3
95
8.76M
9.94%
+1.81M
2025Q2
91
7.15M
12.37%
-1.34M
2025Q1
92
8.48M
12.02%
-1.45M
2024Q4
96
10.25M
12.83%
+2.50M
2024Q3
87
7.76M
12.86%
-212.53K
2024Q2
85
7.98M
16.50%
-894.54K
2024Q1
77
8.87M
15.73%
-1.98M
2023Q4
80
8.98M
16.88%
+542.22K
2023Q3
78
8.44M
17.40%
-315.18K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Tejara Capital Ltd.
3.27M
3.8%
+70.83K
+2.22%
Jun 30, 2025
Elsley (David G)
1.24M
1.45%
--
--
Apr 10, 2025
Willner (Michael Jay)
866.59K
1.01%
+80.24K
+10.20%
Sep 06, 2024
Hamer (Andrew Warwick M.D.)
536.61K
0.62%
+70.00K
+15.00%
Sep 08, 2025
AdvisorShares Investments, LLC
857.39K
1%
-125.10K
-12.73%
Jun 30, 2025
Pekos (Peter)
506.04K
0.59%
+38.75K
+8.29%
Apr 10, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
AdvisorShares Pure Cannabis ETF
1.32%
AdvisorShares Pure Cannabis ETF
占比1.32%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Cardiol Therapeutics Inc的前五大股东是谁？
Cardiol Therapeutics Inc 的前五大股东如下：
Tejara Capital Ltd.持有股份：3.27M，占总股份比例：3.80%。
Elsley (David G)持有股份：1.24M，占总股份比例：1.45%。
Willner (Michael Jay)持有股份：866.59K，占总股份比例：1.01%。
Hamer (Andrew Warwick M.D.)持有股份：536.61K，占总股份比例：0.62%。
AdvisorShares Investments, LLC持有股份：857.39K，占总股份比例：1.00%。
Tejara Capital Ltd.持有股份：3.27M，占总股份比例：3.80%。
Elsley (David G)持有股份：1.24M，占总股份比例：1.45%。
Willner (Michael Jay)持有股份：866.59K，占总股份比例：1.01%。
Hamer (Andrew Warwick M.D.)持有股份：536.61K，占总股份比例：0.62%。
AdvisorShares Investments, LLC持有股份：857.39K，占总股份比例：1.00%。
Cardiol Therapeutics Inc的前三大股东类型是什么？
Cardiol Therapeutics Inc 的前三大股东类型分别是：
Tejara Capital Ltd.
Elsley (David G)
Willner (Michael Jay)
Tejara Capital Ltd.
Elsley (David G)
Willner (Michael Jay)
有多少机构持有Cardiol Therapeutics Inc(CRDL)的股份？
截至2025Q4，共有92家机构持有Cardiol Therapeutics Inc的股份，合计持有的股份价值约为11.26M，占公司总股份的7.89%。与2025Q3相比，机构持股有所增加，增幅为-2.05%。
哪个业务部门对Cardiol Therapeutics Inc的收入贡献最大？
在--，--业务部门对Cardiol Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
